#1 Clinical Trials Search in Europe

Pseudoephedrine Hydrochloride

This article discusses clinical trials investigating the use of Pseudoephedrine Hydrochloride, a common decongestant, in various formulations and combinations. These studies primarily focus on bioequivalence assessments, comparing different drug formulations, and exploring the effects of this medication on nasal passages. The trials involve healthy volunteers and patients with conditions such as seasonal allergic rhinitis, providing valuable insights into the drug’s performance and potential applications.

Table of Contents

What is Pseudoephedrine Hydrochloride?

Pseudoephedrine Hydrochloride is a medication commonly used to relieve nasal congestion. It belongs to a class of drugs called decongestants, which work by narrowing blood vessels in the nasal passages, reducing swelling and congestion[1]. This drug is often found in over-the-counter cold and allergy medications.

Medical Uses

Pseudoephedrine Hydrochloride is primarily used to treat symptoms associated with:

  • Seasonal Allergic Rhinitis: Also known as hay fever, this condition causes nasal congestion, sneezing, and runny nose due to allergens like pollen[2].
  • Sinusitis: An inflammation or swelling of the tissue lining the sinuses, which can cause congestion and difficulty breathing[2].
  • Common Cold: While not explicitly mentioned in the trials, pseudoephedrine is often used to relieve nasal congestion associated with the common cold.

Combination Drugs

Pseudoephedrine Hydrochloride is often combined with other medications to provide more comprehensive symptom relief. Some common combinations include:

  • Ibuprofen + Pseudoephedrine HCl: This combination is used to treat pain, fever, and nasal congestion simultaneously. It’s often marketed under brand names like Advil Cold and Sinus or RhinAdvil[3][4].
  • Fexofenadine HCl + Pseudoephedrine HCl: This combination pairs an antihistamine (fexofenadine) with pseudoephedrine to treat allergy symptoms and congestion. It’s commonly known as Allegra-D[1].

Dosage Information

The dosage of Pseudoephedrine Hydrochloride can vary depending on the specific formulation and combination. Some common dosages observed in the clinical trials include:

  • 30 mg in combination with 200 mg of Ibuprofen[3][4]
  • 60 mg in combination with 400 mg of Ibuprofen[5]
  • 240 mg in extended-release formulations, often combined with 180 mg of Fexofenadine[1]

It’s important to note that these dosages are from clinical trials and may not reflect the recommended dosage for all patients. Always follow the instructions provided by your healthcare provider or the medication label.

Clinical Studies and Research

Several clinical studies have been conducted to evaluate the effectiveness and safety of Pseudoephedrine Hydrochloride:

  • Bioequivalence Studies: Multiple trials have compared different formulations of pseudoephedrine-containing medications to ensure they have similar effects in the body. These studies help ensure that generic versions of medications work as well as brand-name versions[3][4][1].
  • Combination Drug Studies: Research has been conducted to evaluate the effectiveness of pseudoephedrine when combined with other medications like ibuprofen or fexofenadine[3][1].
  • Imaging Studies: Some research has used MRI (Magnetic Resonance Imaging) to evaluate how pseudoephedrine affects the nasal passages and sinuses[2].

Potential Side Effects

While the clinical trials data provided doesn’t explicitly list side effects, it’s important to be aware that all medications can have potential side effects. Common side effects of pseudoephedrine may include:

  • Nervousness
  • Difficulty sleeping
  • Dizziness
  • Increased heart rate

It’s worth noting that one study mentioned using pseudoephedrine as a “beta-adrenergic stimulus,” which suggests it can affect heart rate and blood pressure[6]. Always consult with a healthcare provider about potential side effects and interactions with other medications you may be taking.

Aspect Details
Main Focus Bioequivalence studies of Pseudoephedrine Hydrochloride formulations
Common Combinations With Fexofenadine HCl (180 mg) or Ibuprofen (200 mg)
Dosages Studied 30 mg to 240 mg of Pseudoephedrine HCl
Study Conditions Fasting and fed states
Primary Outcomes AUC and Cmax measurements
Special Techniques MRI scanning for nasal passage evaluation
Target Conditions Seasonal Allergic Rhinitis, general decongestant effects
Unique Aspects Investigation of brown adipose tissue activation

FAQ

  • What is the main purpose of the bioequivalence studies involving Pseudoephedrine Hydrochloride? The main purpose of these bioequivalence studies is to compare different formulations of Pseudoephedrine Hydrochloride, often in combination with other drugs like Fexofenadine or Ibuprofen, to established brand-name medications. This helps ensure that generic versions are as effective as their brand-name counterparts.
  • How is Pseudoephedrine Hydrochloride typically combined with other medications in these trials? In the trials, Pseudoephedrine Hydrochloride is often combined with antihistamines like Fexofenadine or pain relievers like Ibuprofen. For example, one study looked at a combination of 240 mg Pseudoephedrine HCl with 180 mg Fexofenadine HCl, while another examined a combination of 30 mg Pseudoephedrine HCl with 200 mg Ibuprofen.
  • What conditions are being targeted in these Pseudoephedrine Hydrochloride trials? While many of the trials involve healthy volunteers to assess bioequivalence, some studies focus on specific conditions. For instance, one trial investigated the use of Pseudoephedrine Hydrochloride in patients with seasonal allergic rhinitis (hay fever) to evaluate its effects on nasal passages.
  • What methods are used to evaluate the effectiveness of Pseudoephedrine Hydrochloride in these trials? The trials use various methods to evaluate effectiveness. Bioequivalence studies typically measure blood concentration levels over time (AUC) and maximum concentration (Cmax). One study also used MRI scanning to assess the drug's effects on nasal passage dimensions following an allergen challenge.
  • Are there any unique aspects to the Pseudoephedrine Hydrochloride trials mentioned? Yes, one interesting aspect is a study that used ephedrine (a related compound) to investigate its effects on brown adipose tissue activation in lean and obese individuals. This study aimed to understand how adrenergic stimulation might differ between these groups, which could have implications for metabolism and weight management.

Ongoing Clinical Trials on Pseudoephedrine Hydrochloride

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study on the Effects of Pseudoephedrine on Cycling Performance in Healthy Volunteers

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

  • Study of GNT0003 and imlifidase in adults with Crigler-Najjar syndrome who require daily phototherapy and have pre-existing AAV8 antibodies

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness and Safety of Dupilumab for Adults with Chronic Itch of Unknown Cause

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Italy Poland Spain

  • Study on the Safety and Effectiveness of mRNA-3927 for Patients with Propionic Acidemia

    Recruiting

    1 1 1
    Investigated drugs:
    France Italy The Netherlands Spain

  • Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Long-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

    Not recruiting

    1 1 1
    Investigated drugs:
    Czechia France Germany Italy The Netherlands Portugal +1

  • Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France The Netherlands

  • Study to Evaluate mRNA-3210 for Safety and Tolerability in Patients with Phenylketonuria

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • Bioequivalence: A comparison of the biological equivalence of two products with the same active ingredient. In drug testing, it often refers to comparing a generic drug to a brand-name drug to ensure they have the same effect in the body.
  • AUC (Area Under the Curve): A measurement used in bioequivalence studies that represents the total exposure to a drug over time. It's calculated from a graph of drug concentration in the blood versus time.
  • Cmax: The maximum concentration of a drug in the blood after it's been administered. This is another key measurement in bioequivalence studies.
  • Extended Release (ER): A formulation of a drug designed to release the active ingredient slowly over time, allowing for less frequent dosing.
  • Crossover study: A type of clinical trial where participants receive different treatments in a specific order, with each participant serving as their own control.
  • Fasting conditions: A state where participants have not eaten for a certain period before taking the medication, typically used to assess how the drug is absorbed without interference from food.
  • Fed conditions: A state where participants have eaten before taking the medication, used to assess how food affects the drug's absorption and effectiveness.
  • Brown Adipose Tissue (BAT): A type of fat tissue that generates heat by burning calories, potentially playing a role in metabolism and weight management.
  • Positron Emission Tomography-Computed Tomography (PET-CT): An imaging technique that combines PET and CT scans to provide detailed pictures of structures inside the body and their function.
  • Adrenergic receptor: A class of receptors that are targets for adrenaline and similar substances. Pseudoephedrine acts on these receptors to produce its effects.

References

  1. https://clinicaltrials.gov/study/NCT01133483
  2. https://clinicaltrials.gov/study/NCT00517946
  3. https://clinicaltrials.gov/study/NCT01132222
  4. https://clinicaltrials.gov/study/NCT01131780
  5. https://clinicaltrials.gov/study/NCT02963701
  6. https://clinicaltrials.gov/study/NCT01015794